Roche and Bayer are expanding their companion Dx collaboration; Quest Diagnostics snatched up Summit Health;

> Roche ($RHHBY) and Bayer have expanded their companion diagnostics collaboration into multiple projects. Story

> Harvard Medical School and Columbia University won grants of about $12.3 million this year from the National Institute of Allergy and Infectious Diseases to develop translational research centers focused on molecular diagnostics technologies. Story (reg. req)

> Exosome Diagnostics raised a $27 million Series B round, led by Qiagen ($QGEN) and Arcus Ventures, to help propel its prostate cancer urine test to market. Story

> Seattle's Pacific Biomarkers will use its biomarker assays in a collaboration deal with Shanghai's WuXi PharmaTech ($WX) focused on the development of new treatments. Release

> Quest Diagnostics ($DGX) said it will buy Summit Health, an Arizona company that provides finger-stick diagnostics and other biometric screenings. Financial terms were not disclosed. Release

> NeuroMetrix ($NURO) plans to seek regulatory approval in Japan for its point-of-care test to detect diabetic peripheral neuropathy. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.